An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma

British Journal of Cancer

Volumn 110, Issue 2, 2014, Pages 510-519

  Linton, A ^a   Cheng, Y Y ^a   Griggs, K ^b   Kirschner, M B ^a   Gattani, S ^a   Srikaran, S ^a   Chuan Hao Kao, S ^a   McCaughan, B C ^c   Klebe, S ^b   Van Zandwijk, N ^a   Reid, G ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

CDK1; malignant mesothelioma; NDC80; PLK1; RNAi

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN DEPENDENT KINASE 1; INH 1; NDC80 COMPLEX; POLO LIKE KINASE 1; PROTEIN INHIBITOR; ROSCOVITINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AZD 7726; GEMCITABINE; PROTEIN SERINE THREONINE KINASE INHIBITOR;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE REGULATION; DNA REPAIR; DNA REPLICATION; FEMALE; GENE; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TISSUE MICROARRAY; ANTINEOPLASTIC ACTIVITY; CANCER PROGNOSIS; CDK1 GENE; CELL CYCLE PROGRESSION; COLONY FORMATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIZATION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC SCREENING; HUMAN TISSUE; MESOTHELIOMA CELL LINE; NDC80 GENE; ONCOGENE; PLK1 GENE; REAL TIME POLYMERASE CHAIN REACTION;

APOPTOSIS; BLOOD PROTEINS; CDC2 PROTEIN KINASE; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CISPLATIN; DNA REPAIR; DNA REPLICATION; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; PLEURAL NEOPLASMS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PURINES; RETROSPECTIVE STUDIES; RNA INTERFERENCE;

EID: 84892908601     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.731     Document Type: Article

References (49)

1. Abaza MS, Bahman AM, Al-Attiyah RJ (2008) Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells. World J Gastroenterol 14(33): 5162-5175.
2. Androic I, Kramer A, Yan R, Rodel F, Gatje R, Kaufmann M, Strebhardt K, Yuan J (2008) Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol. BMC Cancer 8: 391.
3. Appleyard MV, O'Neill MA, Murray KE, Paulin FE, Bray SE, Kernohan NM, Levison DA, Lane DP, Thompson AM (2009) Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer 124(2): 465-472.
4. Bieche I, Vacher S, Lallemand F, Tozlu-Kara S, Bennani H, Beuzelin M, Driouch K, Rouleau E, Lerebours F, Ripoche H, Cizeron-Clairac G, Spyratos F, Lidereau R (2011) Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy. Mol Cancer 10: 23.
5. Byrne A, McLaren RP, Mason P, Chai L, Dufault MR, Huang Y, Liang B, Gans JD, Zhang M, Carter K, Gladysheva TB, Teicher BA, Biemann HP, Booker M, Goldberg MA, Klinger KW, Lillie J, Madden SL, Jiang Y (2010) Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence. Exp Cell Res 316(2): 258-271.
6. Castedo M, Perfettini JL, Roumier T, Kroemer G (2002) Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 9(12): 1287-1293.
7. Chae SW, Sohn JH, KimDH, Choi YJ, Park YL,KimK, Cho YH, Pyo JS,KimJH (2011) Overexpressions of Cyclin B1, cdc2, p16 and p53 in human breast cancer: the clinicopathologic correlations and prognostic implications. Yonsei Med J 52(3): 445-453.
8. de Oliveira JC, Brassesco MS, Pezuk JA, Morales AG, Valera ET, Montaldi AP, Sakamoto-Hojo ET, Scrideli CA, Tone LG (2012) In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. J Drugs Dermatol 11(5): 587-592.
9. Diaz-Rodriguez E, Sotillo R, Schvartzman JM, Benezra R (2008) Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivo. Proc Natl Acad Sci USA 105(43): 16719-16724.
10. Ellis PM, Chu QS, Leighl N, Laurie SA, Fritsch H, Gaschler-Markefski B, Gyorffy S, Munzert G (2013) A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. Clin Lung Cancer 14(1): 19-27.
11. Feng B, Wang R, Chen LB (2012) MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett 317(2): 184-191.
12. Frost A, Mross K, Steinbild S, Hedbom S, Unger C, Kaiser R, Trommeshauser D, Munzert G (2012) Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Curr Oncol 19(1): e28-e35.
13. Gurzov EN, Izquierdo M (2006) RNA interference against Hec1 inhibits tumor growth in vivo. Gene Ther 13(1): 1-7.
14. Han DP, Zhu QL, Cui JT, Wang PX, Qu S, Cao QF, Zong YP, Feng B, Zheng MH, Lu AG (2012) Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Med Sci Monit 18(6): BR237-BR246.
15. Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, Knipstein J, Dubuc A, Taylor MD, Handler MH, Foreman NK, Vibhakar R (2012) Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. BMC Cancer 12: 80.
16. Hofheinz RD, Al-Batran SE, Hochhaus A, Jager E, Reichardt VL, Fritsch H, Trommeshauser D, Munzert G (2010) An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 16(18): 4666-4674.
17. Hu K, Law JH, Fotovati A, Dunn SE (2012) Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. Breast Cancer Res 14(1): R22.
18. Hui D, Reiman T, Hanson J, Linford R, Wong W, Belch A, Lai R (2005) Immunohistochemical detection of cdc2 is useful in predicting survival in patients with mantle cell lymphoma. Mod Pathol 18(9): 1223-1231.
19. Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M, Matsuura N (2000) Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology 59(1): 68-74.
20. Kao SC, Klebe S, Henderson DW, Reid G, Chatfield M, Armstrong NJ, Yan TD, Vardy J, Clarke S, van Zandwijk N, McCaughan B (2011a) Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol 6(11): 1923-1929.
21. Kao SC, Lee K, Armstrong NJ, Clarke S, Vardy J, van Zandwijk N, Reid G, Burn J, McCaughan BC, Henderson DW, Klebe S (2011b) Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology 43(2): 128-132.
22. Kao SC, Lee K, Klebe S, Henderson D, McCaughan B, Vardy J, Clarke S, van Zandwijk N (2013) Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma. Clin Lung Cancer 14(2): 164-171.
23. Kawata E, Ashihara E, Maekawa T (2011) RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers. J Clin Bioinforma 1(1): 6.
24. Kim SJ, Nakayama S, Miyoshi Y, Taguchi T, Tamaki Y, Matsushima T, Torikoshi Y, Tanaka S, Yoshida T, Ishihara H, Noguchi S (2008) Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. Ann Oncol 19(1): 68-72.
25. King SI, Purdie CA, Bray SE, Quinlan PR, Jordan LB, Thompson AM, Meek DW (2012) Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom. Breast Cancer Res 14(2): R40.
26. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R (2002) Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 29(6): 354-358.
27. Lane HA, Nigg EA (1996) Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 135(6 Pt 2): 1701-1713.
28. Lanphear BP, Buncher CR (1992) Latent period for malignant mesothelioma of occupational origin. J Occup Med 34(7): 718-721.
29. Le Tourneau C, Faivre S, Laurence V, Delbaldo C, Vera K, Girre V, Chiao J, Armour S, Frame S, Green SR, Gianella-Borradori A, Dieras V, Raymond E (2010) Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 46(18): 3243-3250.
30. Li L, Yang L, Scudiero DA, Miller SA, Yu ZX, Stukenberg PT, Shoemaker RH, Kotin RM (2007) Development of recombinant adeno-associated virus vectors carrying small interfering RNA (shHec1)-mediated depletion of kinetochore Hec1 protein in tumor cells. Gene Ther 14(10): 814-827.
31. Linton A, Vardy J, Clarke S, van Zandwijk N (2012) The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma. Crit Rev Oncol Hematol 84(2): 200-212.
32. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4): 402-408.
33. Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, Illei PB, Hussain S, Krug L, Zakowski MF, Rusch V, Olshen AB, Ladanyi M (2006) Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 66(6): 2970-2979.
34. Meyer A, Merkel S, Bruckl W, Schellerer V, Schildberg C, Campean V, Hohenberger W, Croner RS (2009) Cdc2 as prognostic marker in stage UICC II colon carcinomas. Eur J Cancer 45(8): 1466-1473.
35. Mgbonyebi OP, Russo J, Russo IH (1998) Roscovitine inhibits the proliferative activity of immortal and neoplastic human breast epithelial cells. Anticancer Res 18(2A): 751-755.
36. Nigg EA (1998) Polo-like kinases: positive regulators of cell division from start to finish. Curr Opin Cell Biol 10(6): 776-783.
37. Pandha HS, Protheroe A, Wylie J, Parker C, Chambers J, Bell S, Munzert G (2008) An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol 26(15S): 14547.
38. Pass HI, Liu Z, Wali A, Bueno R, Land S, Lott D, Siddiq F, Lonardo F, Carbone M, Draghici S (2004) Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 10(3): 849-859.
39. Relan V, Morrison L, Parsonson K, Clarke BE, Duhig EE, Windsor MN, Matar KS, Naidoo R, Passmore L, McCaul E, Courtney D, Yang IA, Fong KM, Bowman RV (2013) Phenotypes and karyotypes of human malignant mesothelioma cell lines. PLoS One 8(3): e58132.
40. Roe OD, Anderssen E, Sandeck H, Christensen T, Larsson E, Lundgren S (2010) Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer 67(1): 57-68.
41. Romagnoli S, Fasoli E, Vaira V, Falleni M, Pellegrini C, Catania A, Roncalli M, Marchetti A, Santambrogio L, Coggi G, Bosari S (2009) Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis. Am J Pathol 174(3): 762-770.
42. Sebastian M, Reck M,Waller CF, Kortsik C, Frickhofen N, Schuler M, Fritsch H, Gaschler-Markefski B, Hanft G, Munzert G, von Pawel J (2010) The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol 5(7): 1060-1067.
43. Singhal S, Wiewrodt R, Malden LD, Amin KM, Matzie K, Friedberg J, Kucharczuk JC, Litzky LA, Johnson SW, Kaiser LR, Albelda SM (2003) Gene expression profiling of malignant mesothelioma. Clin Cancer Res 9(8): 3080-3097.
44. Spankuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K (2006) Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 66(11): 5836-5846.
45. Tyagi S, Bhui K, Singh R, Singh M, Raisuddin S, Shukla Y (2010) Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73alpha in p53 mutant human epidermoid squamous carcinoma cells. Biochem Pharmacol 80(9): 1326-1334.
46. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14): 2636-2644.
47. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rubsamen-Waigmann H, Strebhardt K (1997) Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 14(5): 543-549.
48. Wong RP, Aguissa-Toure AH, Wani AA, Khosravi S, Martinka M, Li G (2012) Elevated expression of Rad18 regulates melanoma cell proliferation. Pigment Cell Melanoma Res 25(2): 213-218.
49. Wu G, Qiu XL, Zhou L, Zhu J, Chamberlin R, Lau J, Chen PL, Lee WH (2008) Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. Cancer Res 68(20): 8393-8399.